All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
HONG KONG – China’s Shanghai Junshi Biosciences Co. Ltd. has struck a deal with Merck KGaA for a clinical trial program in China to investigate the efficacy and safety of Junshi’s anti-PD-1 monoclonal antibody (MAb), Tuoyi (toripalimab) in combination with Merck’s Erbitux (cetuximab) as a treatment for recurrent and/or metastatic squamous cell carcinomas of the head and neck (SCCHN).
HONG KONG – Two Chinese biotech companies, Hutchison China Meditech Ltd. (Chi-Med) and Beigene Ltd., are teaming up to evaluate their therapies as combination treatments for several cancers and in different key markets.
BEIJING – Suzhou, China-based Innovent Biologics Inc. is known in China as one of the first drugmakers to launch a PD-1 monoclonal antibody. Now, the company is moving to expand its product portfolio and enhance efforts in developing bispecific antibodies and cell therapies in a potential multibillion-dollar deal with pharma giant Roche Holding AG.
LONDON – Evox Therapeutics Ltd. sealed a $1.2 billion collaboration with Eli Lilly and Co. to apply its exosome technology to the doubly difficult task of systemically delivering RNA interference and antisense oligonucleotide drugs, to reach central nervous system targets.
HONG KONG – Israel-based Vayyar Imaging Ltd. and Hong Kong-based Meditemi Co. Ltd. have teamed up to create a more intelligent care robot that provides a range of remote monitoring capabilities, including early detection of COVID-19 symptoms.
HONG KONG – Two Chinese biotech companies, Hutchison China Meditech Ltd. (Chi-Med) and Beigene Ltd., are teaming up to evaluate their therapies as combination treatments for several cancers and in different key markets.
Toronto-based Titan Medical Inc. has inked a development and license agreement with Medtronic plc, of Dublin, to advance the development of single-port robotic-assisted surgical tools. A separate agreement gives Medtronic licensing rights to certain Titan intellectual property. The arrangement aligns with Medtronic’s goal of building its robotic-assisted surgery business and gives Titan’s financials a needed shot in the arm.
Accent Therapeutics Inc. will receive $55 million up front and as much as $1.1 billion in milestones as part of a substantial new three-molecule deal with Astrazeneca plc, which committed to exploring what Astrazeneca’s oncology chief, José Baselga, called the "compelling" field of targeting RNA-modifying proteins (RMPs) for the treatment of cancer.
HONG KONG – China’s Shanghai Junshi Biosciences Co. Ltd. has struck a deal with Merck KGaA for a clinical trial program in China to investigate the efficacy and safety of Junshi’s anti-PD-1 monoclonal antibody (MAb), Tuoyi (toripalimab) in combination with Merck’s Erbitux (cetuximab) as a treatment for recurrent and/or metastatic squamous cell carcinomas of the head and neck (SCCHN).
Prescient Therapeutics Pty Ltd. is poised to develop next-generation CAR T therapies after signing a deal with the University of Pennsylvania for a universal immune receptor technology platform.
RSS
